Business
Issue of Equity and Total Voting Rights
Issue of Equity and Total Voting Rights.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 1660X Angle PLC 26 August 2015 \n \n\nANGLE plc \n(\"ANGLE\" or \"the Company\")\n \nIssue of Equity and Total Voting Rights\n \n \nANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, announces that it has received notice from a former employee to exercise options over 4,000 ordinary shares of 10p each in the Company. \n \nAccordingly the Company has allotted 4,000 new ordinary shares of 10p each (\"New Ordinary Shares\") in the capital of the Company. The New Ordinary Shares rank pari passu with the existing ordinary shares in the Company. An application has been made for the New Ordinary Shares to be admitted to trading on AIM and admission is expected to take place at 8.00 am on 2 September 2015. Following this allotment, the total issued share capital of the Company is 58,978,338 ordinary shares. The figure of 58,978,338 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.\n \n \nFor further information:\n \n\n\n\n\nANGLE plc\n\n\n01483 685830\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\n \n\n\n\n\n\n\n\nCenkos Securities\nStephen Keys, Dr Christopher Golden (Nominated adviser)\nRussell Kerr, Olly Baxendale (Sales) \n \n\n\n020 7397 8900\n\n\n\n\nFTI Consulting\nSimon Conway, Mo Noonan, Stephanie Cuthbert\nKimberley Ha (US) \n\n\n \n020 3727 1000\n001 212 850 5612\n\n\n\n\n \nNotes for editors\n \nAbout ANGLE plc \n \nANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.\n \nANGLE's cell separation technology, known as the Parsortix system, harvests the cells of interest through a liquid biopsy, with the patient only experiencing a simple blood test. Parsortix is the subject of two granted US patents, granted patents in China and Australia and three extensive families of patents being progressed worldwide. The system is based on a microflui...